The Globe and Mail
🏢 Globe and Mail Inc. (Woodbridge)
Aug 4, 2026
· 4 min read
Quick Score
○ Unverifiable
View full audit trail →
Merck’s sales rise more than expected, lifts full-year outlook
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
0.000 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.083
9,110 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
Merck’s sales rise more than expected, lifts full-year outlook
MICHAEL ERMAN
REUTERS
PUBLISHED 1 HOUR AGO
COMMENTS
SHARE
SAVE FOR LATER
Listen to this article
Learn more about audio
Log in or create a free account to listen to this article.
Key takeaways
This summary is AI-generated and editor reviewed. Learn more
Merck reported second-quarter revenue of US$16.61-billion, up 5 per cent year-over-year, beating analyst estimates.
Sales of Keytruda, the world’s top-selling prescription medicine, rose 5 per cent to US$8.37-billion, driven partly by its newer subcutaneous formulation, Keytrud…
Read full article at The Globe and Mail ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.